Real‐World Effectiveness and Safety of a Tubeless Automated Insulin Delivery System With an Adaptive Control Algorithm ( APGO ) in Children and Adolescents With Type 1 Diabetes: A Multicentre Observational Study
Authors' conclusion
In routine paediatric care, use of this tubeless AID system was associated with rapid and sustained improvements in glycaemic control without increased hypoglycaemia.
Study context
- Population
- Children and adolescents with T1D initiating TouchCare Nano automated insulin delivery (AID) therapy; mean age 13.3 ± 3.2 years76 completed follow-up
- Exposure
- TouchCare Nano AID: baseline vs follow-up
- Outcome
- Change in TIR (70-180 mg/dL)
- Follow-up
- Baseline and 1, 3 and 6 months
Methodological detailsmulticentre, single-group, followed for 6 months
- Multicentre
- Single-group
- Followed for 6 months
Main finding
As reported in the abstract
TIR
- Mean time in range (TIR) at baseline
- 59.0% ± 15.6%
- Mean TIR at 1 month
- 74.2% ± 8.9%
- TIR remained significantly higher at 3 and 6 months
- all p < 0.05
Observational data: associations, not effects.
Secondary outcomes
Time in tight range (TiTR), TAR and TBR
- TiTR significantly improved, TAR decreased and TBR remained stable
ISPAD target TIR > 70% · 6 months
- More than half of participants achieved the ISPAD target of TIR > 70%
Mean sensor glucose and glucose variability
- Mean sensor glucose and glucose variability declined
HbA1c · 3 and 6 months
- HbA1c at baseline
- 7.4% ± 0.8%
- HbA1c at 3 and 6 months
- 6.9% ± 0.7%
- HbA1c decrease
- all p < 0.05
Safety
- Episodes of severe hypoglycaemia or DKA
- 0
Original publication
Real‐World Effectiveness and Safety of a Tubeless Automated Insulin Delivery System With an Adaptive Control Algorithm ( APGO ) in Children and Adolescents With Type 1 Diabetes: A Multicentre Observational Study. Diabetes Obes Metab. Published 23 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →